Background: A common misconception is that oncology clinical trials (CT) are a last resort for those who have exhausted treatments or are in advanced stages. This is reflected in the patient (pt) population seeking CT and the greater focus on CT tailored to progressive, refractory, or recurrent diseases. Due to effective screening and its natural progression, prostate cancer (PC) is discovered relatively early, compared to other cancers. Effective, sophisticated non-systemic approaches for treatment are also available in the clinical and also within CT for this cancer. In this study, using real-world pt data, we explored whether those differences impact the way PC pts digitally search for CT. Methods: Leal Health, an AI-based platform, matches cancer pts to CT using pt-reported questionnaires to create individual clinical profiles. These profiles include disease status, stage, biomarkers, treatment history, diversity, and demographics. We analyzed a cohort of 35,671 pt profiles, comparing different clinical and non-clinical parameters between PC pts and those with other solid tumors (bladder, CRC, lung, breast). Results: Leal's data revealed a significantly greater proportion of newly diagnosed PC pts who actively pursued CT, in comparison to individuals diagnosed with other solid tumors (49% vs. 32%, p<0.0001). Additionally, there were significantly fewer available PC trials for newly diagnosed pts compared to relapsed/refractory cases (p<0.0001). The increase in matched trials was 1.61-fold for relapsed/refractory PC pts (p<0.0001) and 2.08-fold for pts with other solid tumors (p<0.0001). A stratified analysis showed that male gender is not a dominant driver for the difference. PC pts were often diagnosed at earlier stages with better performance status compared to other cancer types (p<0.001 for both comparisons). 51% of newly diagnosed PC pts were at stage 1, compared to only 35% of other solid tumors cancer types were. Furthermore, 12% of newly diagnosed PC cases had metastatic disease compared to 26% for other solid tumors. Conclusions: Our research highlights a shift in the traditional pt decision-making, with PC pts showing proactive interest in CT much earlier in their journey compared to other cancers. Male gender alone does not account for this significant difference, which is primarily linked to PC type. While more research is needed, immediate implications and opportunities arise. For example, the significant representation of newly diagnosed PC pts in the digital space represents an opportunity to introduce CT options to pts through this channel and invest in research and trial designs for those pt populations who are not adhering to the traditional standard of care approach before exploring CTs.